Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy

TOKYO, September 1, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) announced that it has voluntarily paused screening and dosing of additional participants in its...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials